Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 28(5): 1998-2004, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38497882

ABSTRACT

OBJECTIVE: In recent years, an overwhelming association between Pediatric Type 1 Diabetes Mellitus (T1DM) and autoimmune diseases has been largely reported. The current study was designed to determine a possible association between autoimmune thyroiditis (AIT), celiac disease (CD) - associated autoantibodies, and Parvovirus B19 infection among pediatric T1DM cases in the southwestern region of Saudi Arabia. PATIENTS AND METHODS: Blood samples from age groups 1-18 years attending the Diabetic Clinic were collected over a period of 12 months. Serum anti-thyroid peroxidase (TPO), anti-thyroglobulin (TG), anti-tissue transglutaminase immunoglobulin A (TG-IgA), endomysial IgA (EMA-IgA), Parvovirus B19-IgG and IgM antibodies were detected by standard methods. RESULTS: The results showed the prevalence of autoantibodies against thyroid and CD among pediatric T1DM patients to be 44 (25%) and 25 (14.4%), respectively. The prevalence of antibodies against B19 was 70 (40%). Further determination of the prevalence of Parvovirus B19-IgG antibodies and thyroid antibodies among T1DM pediatric patients revealed that there was a significant association between them with a p<0.0491. CONCLUSIONS: The prevalence of autoantibodies against the thyroid was higher among the seropositive Parvovirus B19 children with T1DM. A positive association between the prevalence of autoantibodies against thyroid disease and the increase in the duration of diabetes was also noted. Hence, periodic screening of T1DM patients for B19 antibodies and autoantibodies for thyroid is crucial.


Subject(s)
Celiac Disease , Diabetes Mellitus, Type 1 , Parvovirus B19, Human , Humans , Child , Infant , Child, Preschool , Adolescent , Thyroid Gland , Autoantibodies , Antibodies, Viral , Immunoglobulin G , Celiac Disease/epidemiology , Immunoglobulin A
2.
Trop Biomed ; 37(4): 1062-1073, 2020 Dec 01.
Article in English | MEDLINE | ID: mdl-33612758

ABSTRACT

Pandemic H1N1 influenza virus respiratory illness has become an inevitable global health concern. With antigenic drift, it becomes necessary to have drugs over tailor-made HIN1 vaccine every year. In the current study, we screened many Piperine derivative in which, N-5-(3,4-dimethoxyphenyl)-2E,4E-pentadienylpiperidine (AB05) and was further studied for anti-H1N1influenza virus activity and compared with other stains in-vitro on MDCK cell line. Initial cytotoxic doses of AB05 for the MDCK cell line were > 25µM. The results showed a dose-dependent reduction of the viral plaque's in the adsorption assay with EC50 of 0.33 µM. The mechanism of AB05 was by inhibition of matured viral release as evaluated by the time of virus addition with incubation of 6-10 hours. With the promising H1N1 virucidal activity of AB05, we included various strains of human influenza virus to screen AB05 inhibition of Neuraminidase (NA). The result showed 70% NA inhibition in WSN (H1N1), 90% in H3N2 and Influenza B and 49% in Tamiflu resistant H1N1). Further our In silco docking studies substantiated experimental results by showing the difference in binding and cooperation between H1N1 and N3N2. Together these observations illustrate that Piperine derivative AB05 is a promising lead molecule which needs further evaluation in animal models.


Subject(s)
Alkaloids/pharmacology , Antiviral Agents/pharmacology , Benzodioxoles/pharmacology , Influenza A Virus, H1N1 Subtype/drug effects , Neuraminidase/antagonists & inhibitors , Piperidines/pharmacology , Polyunsaturated Alkamides/pharmacology , Viral Proteins/antagonists & inhibitors , Animals , Dogs , Madin Darby Canine Kidney Cells , Molecular Docking Simulation , Molecular Structure , Piper/chemistry , Protein Structure, Tertiary
3.
Tropical Biomedicine ; : 1062-1073, 2020.
Article in English | WPRIM (Western Pacific) | ID: wpr-862624

ABSTRACT

@# Pandemic H1N1 influenza virus respiratory illness has become an inevitable global health concern. With antigenic drift, it becomes necessary to have drugs over tailor-made HIN1 vaccine every year. In the current study, we screened many Piperine derivative in which, N-5-(3,4-dimethoxyphenyl)-2E,4E-pentadienylpiperidine (AB05) and was further studied for anti-H1N1influenza virus activity and compared with other stains in-vitro on MDCK cell line. Initial cytotoxic doses of AB05 for the MDCK cell line were > 25µM. The results showed a dose-dependent reduction of the viral plaque’s in the adsorption assay with EC50 of 0.33 µM. The mechanism of AB05 was by inhibition of matured viral release as evaluated by the time of virus addition with incubation of 6-10 hours. With the promising H1N1 virucidal activity of AB05, we included various strains of human influenza virus to screen AB05 inhibition of Neuraminidase (NA). The result showed 70% NA inhibition in WSN (H1N1), 90% in H3N2 & Influenza B and 49% in Tamiflu resistant H1N1). Further our In silco docking studies substantiated experimental results by showing the difference in binding and cooperation between H1N1 and N3N2. Together these observations illustrate that Piperine derivative AB05 is a promising lead molecule which needs further evaluation in animal models.

4.
Indian J Med Microbiol ; 34(4): 553-557, 2016.
Article in English | MEDLINE | ID: mdl-27934844

ABSTRACT

A 5-year-old female child presented with fever of 1-week duration after visiting a malaria endemic zone without antimalarial prophylaxis. The patient presented with respiratory distress, decreased level of consciousness and high-grade fever. An elevated parasitaemia reaching 800,000/µl was observed. Antimalarial therapy was initiated with artesunate being administered intravenous (IV) along with IV clindamycin. Contrary to the expectations, there was no resolution of fever. Following a week of unresolved fever, the drug therapy was revised and altered to IV quinine dihydrochloride and IV clindamycin. Emergence of non-responsiveness to artesunate in Saudi Arabia is an alarming sign and requires revision of management protocols.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/diagnosis , Malaria, Falciparum/drug therapy , Administration, Intravenous , Artesunate , Child, Preschool , Clindamycin/therapeutic use , Drug Resistance , Female , Humans , Quinine/therapeutic use , Saudi Arabia , Treatment Failure
5.
J Mycol Med ; 25(1): 17-22, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25497707

ABSTRACT

Chloramphenicol is a bacteriostatic antimicrobial agent but its antifungal activity is not known. The present study aimed to investigate the activity of chloramphenicol against 30 representative yeasts. The antimicrobial assay of chloramphenicol (50mg/mL; 100mg/mL and 200mg/mL) was determined by the disc diffusion method using Mueller-Hinton agar against 30 representative yeast strains. Zone of inhibition was read after 48-72h incubation at 37°C and results were compared with some standard antifungal agents. Most of the tested yeasts (73.3%) showed inhibition zones (5 up to 35mm) to chloramphenicol impregnated discs (200mg/mL). Three out of the four tested Candida albicans as well as Candida famata, Candida glabrata, Candida haemolonei and Cryptococcus neoformans showed no inhibition zones to chloramphenicol (200mg/mL). Caspofungin acetate (50mg/mL) inhibited 83.3% of the strains; ketoconazole (200mg/mL) 70% and metronidazole 10%. Chloramphenicol discs: 50 and 100mg/mL showed less activity (6.7% and 36.7%, respectively) compared to the 200mg discs; whereas chloramphenicol (BBL; 3µg/mL) inhibited 13.3% of the strains. The anti-yeast activities of chloramphenicol were comparable to other known antifungal compounds. Moreover, it is cheap, has fewer side effects and its inclusions in selective fungal media such as Mycosel have to be questioned.


Subject(s)
Antifungal Agents/pharmacology , Chloramphenicol/pharmacology , Candida/drug effects , Caspofungin , Cryptococcus neoformans/drug effects , Echinocandins/pharmacology , Fluconazole/pharmacology , Humans , Ketoconazole/pharmacology , Lipopeptides , Microbial Sensitivity Tests , Pilot Projects , Saccharomyces cerevisiae/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...